Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages?

Therapeutic Advances in Medical Oncology
Griet DeslypereJohan Vansteenkiste

Abstract

Over the last decade, several steps forward in the treatment of patients with stage IV non-small cell lung cancer (NCSLC) were made. Examples are the use of pemetrexed, pemetrexed maintenance therapy, or bevacizumab for patients with nonsquamous NSCLC. A big leap forward was the use of tyrosine kinase inhibitors in patients selected on the basis of an activating oncogene, such as epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK) translocations. However, all of these achievements could not be translated into survival benefits when studied in randomized controlled trials in patients with nonmetastatic NSCLC. Aside from chemotherapy and targeted therapy, immunotherapy has become the third pillar in the treatment armamentarium of advanced NSCLC. Antigen-specific immunotherapy (cancer vaccination) has been disappointing in large phase III clinical trials in stages I-III NSCLC. Based on the recent breakthroughs with immune checkpoint inhibitor immunotherapy in metastatic NSCLC, much hope currently rests on the use of this approach in patients with stage I-III NSCLC as well. Here we give a brief overview of how most new therapeutic approaches for advanced NSCLC failed in other stages, and...Continue Reading

References

Jan 23, 2004·The New England Journal of Medicine·Rodrigo ArriagadaUNKNOWN International Adjuvant Lung Cancer Trial Collaborative Group
Feb 28, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A AupérinUNKNOWN Meta-Analysis of Cisplatin/carboplatin based Concomitant Chemotherapy in non-small cell Lung Cancer (MAC3-LC) Group
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
Apr 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Karen KellyDavid R Gandara
May 29, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giorgio Vittorio ScagliottiDavid Gandara
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Mar 31, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anne AupérinJean-Pierre Pignon
Jan 31, 2012·The Lancet Oncology·Rafael RosellUNKNOWN Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia T
Nov 20, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M KreuterUNKNOWN TREAT investigators
May 30, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fernando Ulloa-MontoyaVincent G Brichard
May 30, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Johan VansteenkisteVincent G Brichard
Jul 3, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lecia V SequistMartin Schuler
Jul 19, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J VansteenkisteUNKNOWN ESMO Guidelines Working Group
Aug 28, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Glenwood D GossFrances A Shepherd
Dec 4, 2014·The New England Journal of Medicine·Benjamin J SolomonUNKNOWN PROFILE 1014 Investigators
Apr 16, 2015·Cancer Treatment Reviews·Kobe ReyndersDirk De Ruysscher
Sep 2, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Karen KellyFrances A Shepherd
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Jan 15, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Peter GoldstrawUNKNOWN International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Particip
Jan 15, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Michael KreuterUNKNOWN TREAT investigators
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Jan 14, 2017·Current Opinion in Oncology·Dirk De RuysscherMaarten Lambrecht
Jan 18, 2017·Nature Reviews. Clinical Oncology·Ralph R WeichselbaumYang-Xin Fu
Jun 7, 2017·The New England Journal of Medicine·Solange PetersUNKNOWN ALEX Trial Investigators
Sep 9, 2017·The New England Journal of Medicine·Scott J AntoniaUNKNOWN PACIFIC Investigators
Nov 21, 2017·The New England Journal of Medicine·Jean-Charles SoriaUNKNOWN FLAURA Investigators
Jul 1, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P E PostmusUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

❮ Previous
Next ❯

Citations

May 31, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J VansteenkisteD De Ruysscher
Jun 7, 2020·Cancers·Maria Joana CatarataRui Medeiros

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection
dissection

Clinical Trials Mentioned

NCT00480025
NCT02519322
NCT02125461
NCT02768558
NCT02343952
NCT02621398
NCT02525757

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.